Rofleponide
Alternative Names: Rofleponide palmitate; RPL; RPNSLatest Information Update: 25 Sep 2021
Price :
$50 *
At a glance
- Originator AstraZeneca Pharmaceuticals
- Developer AstraZeneca Pharmaceuticals; Draco Lakemedel
- Class Antiallergics; Antiasthmatics; Glucocorticoids
- Mechanism of Action Arachidonic acid inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Allergic rhinitis; Asthma; Inflammatory bowel diseases
Most Recent Events
- 07 Feb 2003 Discontinued - Phase-II for Allergic rhinitis in Europe (Intranasal)
- 07 Nov 2002 Discontinued - Preclinical for Inflammatory bowel disease in Sweden (Topical)
- 09 Feb 2000 Discontinued-II for Asthma in Sweden (Inhalation)